Effect PEEP on Diaphragm

NCT ID: NCT03539640

Last Updated: 2020-05-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

22 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-04-13

Study Completion Date

2019-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the effect of positive end-expiratory pressure on the position, length and function of the diaphragm. During the first part of the study, physiological measurements of the diaphragm will be performed while participants receive non-invasive ventilation at different PEEP levels. During the second part of the study, MRI measurements of the diaphragm will be performed during a change in PEEP level.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In almost all mechanically ventilated patients, positive end-expiratory pressure (PEEP) is used. Its function is to prevent alveolar collapse and to maintain oxygenation. However, it has recently been found that PEEP may contribute to diaphragm weakness, which is an important problem in the intensive care unit (ICU). This study showed that mechanical ventilation with PEEP resulted in a caudal displacement of the diaphragm, since PEEP increases the end-expiratory volume. Furthermore, their study in rats showed that this displacement resulted in a reduced fiber length and sarcomere length on the short term.

After rats were ventilated with PEEP for 18 hours, it was found that adaptation of the diaphragm occurred; i.e. the number of sarcomeres were decreased. It is hypothesized that this adaptation may also occur in mechanically ventilated patients. This could lead to problems in weaning a patient off the ventilator, as PEEP is abruptly removed during a spontaneous breathing trial (SBT). This leads to a reduction in end-expiratory volume which would mean that the newly-adapted diaphragm fibers are being stretched. These stretched muscle fibers are not working at their optimal length of the force-length relation, thereby contributing to diaphragm weakness.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diaphragm Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

All participants will receive the same protocol with different levels of PEEP ventilation during the first part of the study (physiological part), so the interventional study model for this part is single group. During the second part (MRI), participants are randomized for one of the three available PEEP levels (5, 10 or 15 cmH2O), so the study model for this part is parallel.
Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Outcome Assessors
The assessor of the MRI measurements will analyze the MRI data in a blinded fashion. The rest of the outcomes will not be analyzed in a blinded fashion.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PEEP level of 5 cmH2O

During second part of the study (MRI) Diaphragm position

Group Type ACTIVE_COMPARATOR

PEEP: 5 cmH2O

Intervention Type OTHER

During second part of the study (MRI)

PEEP level of 10 cmH2O

During second part of the study (MRI) Diaphragm position

Group Type ACTIVE_COMPARATOR

PEEP: 10 cmH2O

Intervention Type OTHER

During second part of the study (MRI)

PEEP level of 15 cmH2O

During second part of the study (MRI) Diaphragm position

Group Type ACTIVE_COMPARATOR

PEEP: 15 cmH2O

Intervention Type OTHER

During second part of the study (MRI)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PEEP: 5 cmH2O

During second part of the study (MRI)

Intervention Type OTHER

PEEP: 10 cmH2O

During second part of the study (MRI)

Intervention Type OTHER

PEEP: 15 cmH2O

During second part of the study (MRI)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed informed consent
* Age ≥ 18 years

Exclusion Criteria

* Symptoms relating to respiratory or cardiovascular disease
* History of pneumothorax or family history of primary pneumothorax
* Obesity (defined as BMI \> 30kg/m²)
* Known pregnancy
* Contraindications for the placement of a nasogastric tube (upper airway/esophageal/gastric/mouth or face pathology (e.g. recent surgery, esophageal varices, diaphragmatic hernia), nasal bleeding within the last 2 weeks or use of anticoagulants)
* Contraindications for MRI (electrical/metallic implants, claustrophobia or history in metalworking)
* Subjects who are employed at the department of intensive care adults, directly involved in the study and/or family from staff of the ICU.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Amsterdam UMC, location VUmc

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Prof.dr. L.M.A. Heunks

MD, PhD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Leo Heunks, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Amsterdam UMC, location VUmc

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

VU Medical Center

Amsterdam, North Holland, Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NL63905.029.17

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.